ONC:NASDAQBeOne Medicines Ltd. analysis
Data as of Oct 4, 2026 - not real-time
- Latest price
- $358.07
- Risk: medium
- 5/10Medium risk
Summary
The moving-average structure behind BeOne Medicines AG is bullish at $358.07, with short-term averages leading the long-term ones. Across the trailing 30 sessions it lost 3.0%. Momentum indicators put RSI at 50.4 (neutral) with MACD reading bearish. The recent range runs from support at $336.95 up to resistance at $376.50.
The shares look overvalued, trading on 64.1 times earnings above a sector average of 29.7. The average analyst target implies 21.1% above today's level. Revenue is growing at 29.6% on a 10.7% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 23.7%, a beta of 0.85 and a maximum drawdown of 31.0%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
The shares look overvalued, trading on 64.1 times earnings above a sector average of 29.7. The average analyst target implies 21.1% above today's level. Revenue is growing at 29.6% on a 10.7% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 23.7%, a beta of 0.85 and a maximum drawdown of 31.0%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.
Top market events
- BeOne Medicines AG NASDAQ:ONC entered a voluntary agreement with the U.
- BeOne Medicines, Ltd. Nasdaq: ONC; HKEX: 06160; SSE: 688235 , a global oncology company, today announced a voluntary...
- BeOne Medicines Ltd. Nasdaq: ONC; HKEX: 06160; SSE: 688235 , a global oncology company, and
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 320.10
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- P/E of 64.1 versus sector average of 29.7
- Trading above the 200-day average of 320.10
Long term
> 3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- P/E of 64.1 versus sector average of 29.7
- Analyst targets imply +21.1% versus the current price
- Revenue growth of +29.6%
Key metrics
Financial health
Revenue Growth29.60%
Profit Margin10.70%
P/E Ratio64.1
ROE14.66%
ROA7.46%
Debt/Equity39.61
P/B Ratio7.8
Op. Cash Flow$1.5B
Free Cash Flow$879.0M
Industry P/E29.7
Technical analysis
TrendBullish
RSI50.4
Support$336.95
Resistance$376.50
MA 20$356.82
MA 50$353.31
MA 200$320.10
MACDBearish
VolumeStable
Fear & Greed Index94.09
Valuation
Fair Value$275.79
Target Price$433.52
Upside/Downside21.07%
GradeOvervalued
TypeGrowth
Risk assessment
Beta0.85
Volatility23.74%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.